825 Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA Study
William Sandborn, Geert D’Haens(Amsterdam University Medical Centers), Walter Reinisch(Medical University of Vienna), Dino Tarabar(Military Medical Academy), Fabio Cataldi(Pfizer (United States)), Dong Il Park(Kangbuk Samsung Hospital), Alaa Ahmad(All India Institute of Medical Sciences), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Édouard Louis(Centre Hospitalier Universitaire de Liège), Mina Hassan‐Zahraee(Pfizer (United States)), Scott D. Lee(University of Washington), Lisa Brown(Pfizer (United States)), John B. Cheng(Pfizer (United States)), Xavier Hébuterne, Kenneth J. Gorelick, Jochen Klaus(University Hospital Ulm), Maria Kłopocka(Nicolaus Copernicus University)
Cited by 16
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k